雌激素、孕激素及其受体与膀胱癌关系的研究进展

舒筠然; 陈晶; 钱佳丽; 柯亭羽

doi:10.13201/j.issn.1001-1420.2018.11.017

雌激素、孕激素及其受体与膀胱癌关系的研究进展

- 昆明医科大学第二附属医院内分泌科(昆明, 650101)
基金项目:
国家自然科学基金 (编号81760327, 81260229, 31260223)

云南省中青年学术和技术带头人后备人才培养项目 (编号2017HB049)

云南省卫生和计划生育委员会医学学科带头人培养计划 (编号D-201626)

云南省卫生科技计划项目 (编号2016NS259)

详细信息

通讯作者: 柯亭羽,E-mail:ketingyu@hotmail.com

中图分类号: R737.14

收稿日期: 2018-05-24

Research progress of the relationship between estrogen, progesterone, their receptors and bladder cancer

- Department of Endocrinology, Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, China

More Information

Corresponding author: KE Tingyu, E-mail: ketingyu@hotmail.com

Received Date: 24 May 2018

摘要

摘要: 性激素分为雌激素、雄激素、孕激素,过去雄激素受体及其相关的信号通道与膀胱癌的研究较多,临床证据表明雄激素及其受体在膀胱癌发生、发展中具有明确的相关性,但雌激素、孕激素及其受体与膀胱癌发生、发展相关性研究较少,对于女性和男性其发病率不同,且膀胱癌肿瘤侵袭程度和进展有所不同,因此研究雌激素、孕激素受体及其相关的信号通路在疾病中的作用,可为改善目前膀胱癌的预防和内分泌治疗提供理论依据和新的思路。本文就此作一综述。
- 雌激素 /
- 雌激素受体 /
- 孕激素 /
- 孕激素受体 /
- 膀胱癌
Abstract: Sex hormones are divided into estrogens, androgens, progestins.There were many studies on the relationship between androgen receptors, their associated signaling pathways and bladder cancer in the past.Clinical evidence showed that androgen and its receptors played a clear role in the occurrence and development of bladder cancer.However, studies on the relationship between estrogen, progesterone, their receptors and the occurrence and development of bladder cancer are rare.For women and men, the incidence is different, and the degree and progress of bladder cancer invasion are different.Therefore, the role of estrogen and progesterone receptors and their related signaling pathways in diseases is studied to provide a theoretical basis and new ideas for improving the current prevention and endocrine therapy of bladder cancer.This article gives an overview of it.
- estrogen /
- estrogen receptor /
- progesterone /
- progesterone receptor /
- bladder cancer

HTML全文

参考文献(34)

[1]	Jemal A, Bray F, Center M M, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2):69-90.
[2]	吴丽媛, 杨飞亚, 邢念增.趋化因子在膀胱癌诊断中作用的研究进展[J].临床泌尿外科杂志, 2018, 33 (6):497-501.
[3]	Torre L A, Bray F, Siegel R L, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2):87-108.
[4]	Najari B B, Rink M, Li P S, et al.Sex disparities in cancer mortality:the risks of being a man in the United States[J].J Urol, 2013, 189 (4):1470-1474.
[5]	Vaidya A, Soloway M S, Hawke C, et al, De novo muscle invasive bladder cancer:is there a change in trend?[J].J Urol, 2001, 165 (1):47-50.
[6]	Otto W, May M, Fritsche H M, et al.Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy:results of a large German multicenter study of nearly 2500patients with urothelial carcinoma of the bladder[J].Gend Med, 2012, 9 (6):481-489.
[7]	Sammon J D, Morgan M, Djahangirian O, et al.Marital status:agender-independent risk factor for poorer survival after radical cystectomy[J].BJU Int, 2012, 110 (9):1301-1309.
[8]	Shariat S F, Sfakianos J P, Droller M J, et al.The effect of age and gender on bladder cancer:a critical review of the literature[J].BJU Int, 2010, 105 (3):300-308.
[9]	Horie S.Editorial comment to Inverse expression of estrogen receptor-beta and nuclear factor-kappaB in urinary bladder carcinogenesis[J].Int J Urol, 2010, 17 (9):810-810.
[10]	Bolenz C, Lotan Y, Ashfaq R, et al.Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder[J].Eur Urol, 2009, 56 (6):1093-1095.
[11]	Xu Y, Zhang N Z, Chen J, et al.Biomarkers in urothelial carcinoma of the bladder:the potential cross-talk between transforming growth factor-β1 and estrogen receptorβ/androgen receptor pathways[J].Med Hypotheses, 2013, 80 (6):716-718.
[12]	Madeb R, Messing E M.Gender, racial and age differences in bladder cancer incidence and mortality[J].Urol Oncol, 2004, 22 (2):86-92.
[13]	Murta-Nascimento C, Schmitz-Drçger B J, Zeegers MP, et al.Epidemiology of urinary bladder cancer:from tumor development to patient's death[J].World J Urol, 2007, 25 (3):285-295.
[14]	Racioppi M, D'Agostino D, Totaro A, et al.Value of current chemotherapy and surgery in advanced and metastatic bladder cancer[J].Urol Int, 2012, 88 (3):249-258.
[15]	Rose T L, Milowsky M I.Improving Systemic Chemotherapy for Bladder Cancer[J].Curr Oncol Rep, 2016, 18 (5):27-27.
[16]	Ding M, Zhan H, Liao X, et al.Enhancer RNA-P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer[J].Int J Biol Sci, 2018, 14 (10):1268-1276.
[17]	程荣璇, 王志华, 王晓秋, 等.膀胱癌的性激素受体检测及其意义[J].临床与实验病理学杂志, 1996, 12 (4):326-328.
[18]	Teng J, Wang Z Y, Jarrard D F, et al.Roles of estrogen receptorα and βin modulating urothelial cell proliferation[J].Endocr Relat Cancer, 2008, 15 (1):351-364.
[19]	Kauffman E C, Robinson B D, Martin D, et al.Estrogen receptor-β expression and pharmacological targeting in bladder cancer[J].Oncol Rep, 2013, 30 (1):131-132.
[20]	Teng J, Wang Z Y, Jarrard D F, et al.Roles of estrogen receptorα and βin modulating urothelial cell proliferation[J].Endocr Relat Cancer, 2008, 15 (1):351-364.
[21]	Croft P R, Lathrop S L, Feddersen R M, et al.Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma[J].Arch Pathol Lab Med, 2005, 129 (2):194-199.
[22]	Boorjian S A, Heemers H V, Frank I, et al.Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder[J].Endocr Relat Cancer, 2009, 16 (1):123-124.
[23]	Mashhadi R, Pourmand G, Kosari F, et al.Role of steroid hormone receptors in formation and progression of bladder carcinoma:a case-control study[J].Urol J, 2014, 11 (6):1968-1971.
[24]	Han B, Cui D, Jing Y, et al.Estrogen receptorβ (ERβ) is a novel prognostic marker of recurrence survival in nonmuscle-invasive bladder cancer potentially by inhibiting cadherin switch[J].World J Urol, 2014, 32 (1):149-155.
[25]	Hill K K, Roemer S C, Churchill M E A, et al.Structural and functional analysis of domains of the progesterone receptor[J].Mol Cell Endocrinol, 2012, 348 (2):418-429.
[26]	Boonyaratanakornkit V, Scott M P, Ribon V, et al.Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases[J].Mol Cell, 2001, 8 (2):269-280.
[27]	颜纯海, 单玉喜, 李玲玲.雌、孕激素受体在膀胱癌中的表达[J].苏州医学院学报, 1994, 6:487-488.
[28]	Wolpert B J, Amr S, Ezzat S, et al.Estrogen exposure and bladder cancer risk in Egyptian women[J].Maturitas, 2010, 67 (4):353-357.
[29]	Daugherty S E, Lacey J V Jr, Pfeiffer R M, et al.Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study[J].Int J Cancer, 2013, 133 (2):462-472.
[30]	Johnson A M, O'Connell M J, Messing E M, et al.Decreased bladder cancer growth in parous mice[J].Urology, 2008, 72 (3):470-473.
[31]	Ide H, Miyamoto H.Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor[J].Dis Markers, 2015, 2015:840640.
[32]	Celayir S, Ilçe Z, Dervisoglu S.The sex hormone receptors in the bladder in childhood-I:preliminary report in male subjects[J].Eur J Pediatr Surg, 2002, 12 (5):312-317.
[33]	Kashiwagi E, Fujita K, Yamaguchi S, et al.Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract[J].Cancer Biol Ther, 2016, 17 (11):1188-1196.
[34]	王庆伟, 张涛, 文建国, 等.上尿路尿路上皮癌预后多因素分析及术后再发膀胱癌危险因素分析[J].临床泌尿外科杂志, 2018, 33 (5):385-389.